Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program (PC-PEP)

March 16, 2026 updated by: Gabriela Ilie

PC-PEP Phase 4: Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

Each year over 20,000 men are diagnosed with prostate cancer in Canada with the majority undergoing some form of treatment option. Radical prostatectomy and/or radiation therapy are common procedures that are effective in the treatment of prostate cancer. However, they typically incur both short- and long-term side effects (e.g. urinary incontinence, sexual dysfunction, reduced physical function, etc) that can negatively impact one's quality of life. This program of research aims to address the most critical needs of PC survivors: the development and evaluation of interventions to address the quality of life impact of PC. This study will test the Prostate Cancer Patient Empowerment Program (PC-PEP) in 400 men, a comprehensive intervention aimed at educating and teaching the men life skills/habits in order to improve their mental health issues, fitness levels and overall quality of life, and to decrease treatment related side effects. The program also aims to improve the overall health of the participants in the long term.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

In a survey study of almost 400 survivors of prostate cancer (PC), the investigators found that 17% of them suffered currently from mental health issues, and most were not on medication to address this issue. Compounding issues included urinary and sexual disfunction, poor attendance to support groups, intimacy, problems sleeping and other health problems. To address these many issues directly, with the endorsement of physicians and patients attending our regional PC integrative care conference (April 2018) and expanding on pre-habitation (pre-surgery) science, the investigators created a Patient Empowerment Program (PEP) to be delivered from day one of diagnosis, to educate and teach the men and partners life skills/habits which are aimed to improve their fitness levels and quality of life, and to decrease treatment related side effects. This program is in line with the Auditor General of Nova Scotia's 2017 report endorsing the use of bottom-up evidence-based interventions, created from actively engaging patients in development and process. The investigators aim to trial PC-PEP for men undergoing curative treatment for PC versus a control group receiving standard care. The PC-PEP program includes in-person and multimedia informational, physical activity, pelvic floor, stress reduction, and relationship/connection training. The men are connected with other participants to increase social support and maximize compliance. Technology is used to deliver daily alerts to patients to remind them to engage in the program. A PC-PEP feasibility study of 30 men, over 28 days, showed that the program is feasible, leads to positive outcomes in patients and is highly (9.79/10) endorsed by patients. It is predicted that PC-PEP will improve mental health (primary outcome) and other quality of life outcomes of patients compared with 'usual care'.

A randomized, wait-list controlled clinical trial for men newly diagnosed with PC is currently underway. This next phase will open the program to more men and expand the inclusion criteria. Participants in the PC-PEP will receive the intervention for six months. Introducing a comprehensive empowerment program from day one of diagnosis may mitigate against the high levels of mental distress, short and long-term, suffered by hundreds of Nova Scotian men undergoing curative PC treatment every year, and the burden that treatment related side effects will place on our health care system. Given that the study has the endorsement of patients, clinicians and administrators at Nova Scotia Health, if proven successful it will have the evidence base needed to change the current standard of care.

Study Type

Interventional

Enrollment (Estimated)

2130

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Belgium
    • East Flanders
      • Ghent, East Flanders, Belgium, 9000
        • Not yet recruiting
        • University Hospital Ghent
        • Contact:
  • Canada
    • Alberta
      • Edmonton, Alberta, Canada, T6G 1Z1
        • Recruiting
        • Dianne and Irving Kipnes Urology Centre
        • Contact:
        • Principal Investigator:
          • Howard Evans, MD
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 5L3
        • Recruiting
        • BC Cancer - Kelowna (Sindi Ahluwalia Hawkins Centre)
        • Contact:
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3K 1M3
        • Recruiting
        • Men's Health Clinic Manitoba
        • Contact:
    • New Brunswick
      • Saint John, New Brunswick, Canada, E2L 4L4
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1B 3V6
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X5
      • Whitby, Ontario, Canada, L1P 0P9
        • Recruiting
        • Whitby Health Centre - Dr. Ernest Chan Medicine Professional Corporation
        • Contact:
          • Ernest Chan, MD
          • Phone Number: (905) 721-3278
          • Email: echan@lh.ca
    • Prince Edward Island
      • Charlottetown, Prince Edward Island, Canada, C1A 8T5
        • Recruiting
        • Queen Elizabeth Hospital
        • Contact:
    • Quebec
    • Saskatchewan
  • New Zealand
  • Romania
    • Transylvania
      • Cluj-Napoca, Transylvania, Romania, 400124
        • Not yet recruiting
        • Medisprof Cancer Center
        • Contact:
  • South Africa
    • Gauteng
      • Ga-Rankuwa, Gauteng, South Africa, 2193
        • Recruiting
        • Sefako Makgatho Health University
        • Contact:
        • Principal Investigator:
          • Shingai Mutambirwa, MD
      • Johannesburg, Gauteng, South Africa, 2193
        • Recruiting
        • Charlotte Maxeke Johannesburg Academic Hospital
        • Contact:
        • Principal Investigator:
          • Duvern Ramiah, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age >18
  • History of a prostate cancer diagnosis
  • Safe to exercise and do strength training (participants who have recovered from a minor stroke or heart condition in the past will require approval from their Family Physician or Cardiologist to participate in the study. Participants with advanced prostate cancer will need approval from the Study Physician or their Urologist or Oncologist to participate)
  • Existing (or willingness to create) email account
  • Willingness to access and use daily email and/or text messages
  • Ability to follow website links to watch YouTube videos
  • Ability to understand and speak English
  • Ability to participate in low to moderate levels of physical activity
  • Ability and willingness to fill out an online survey at baseline, and 6, 12 and 24 months, and a weekly compliance survey for the six months of the program.
  • Deemed to have an expected survival greater than 2 years

Exclusion Criteria:

  • Patients deemed unfit to participate in low level exercise eg. including but not limited to a myocardial infarction or stroke within the last year, without approval from their Family Physician or Cardiologist that they are safe to exercise.
  • Unable to access the internet and lack of a computer or cellphone to receive emails required for study intervention, or unable to click on a link to successfully watch a YouTube video.
  • Men with a predicted survival less than 2 years.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Arm
Behavioral: Patient Empowerment Program
The 6 months "at home" program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mental Health
Time Frame: 6 - 24 months
Kessler 10 - assessment of psychological distress. Measured through on-line survey.
6 - 24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
General Health (Physical and Mental) Quality of Life as assessed by the 12-item Short Form Health Survey (SF-12)
Time Frame: 6 - 24 months
The scale has a score range of 0 to 100, with a higher score indicating a better outcome, and a score of 50 indicating the U.S. population average.
6 - 24 months
Disease Specific Health-Related Quality of Life as assessed by the Functional Assessment of Cancer Therapy-Prostate (FACT-P)
Time Frame: 6 - 24 months
A 39-item questionnaire. The scale has a total score range of 0-156 with a higher score indicating better quality of life.
6 - 24 months
Urinary, Bowel, Hormonal, and Sexual Function as assessed by the Expanded Prostate Cancer Index Composite (EPIC)
Time Frame: 6 - 24 months
A 50-item questionnaire to evaluate patient function and bother after prostate cancer treatment. The scale has a score range of 0-100 with a higher score indicating a better outcome.
6 - 24 months
Urinary Bother as assessed by the International Prostate Symptom Score (IPSS)
Time Frame: 6 - 24 months
A 7-item questionnaire. The scale has a score range of 0-35 with a higher score indicating more severe urinary bother.
6 - 24 months
Health Care Utilization
Time Frame: 6 - 24 months

This will be assessed through the following survey questions:

  1. During the PAST 6 MONTHS, how many TIMES did you visit a doctor or health care provider for physical illness? (do not include visits while you were in the hospital for your Prostate Cancer treatment (e.g., radiation, surgery, etc)?
  2. During the PAST 6 MONTHS, how many TIMES did you visit a doctor or health care provider for a mental health issue?
  3. How many TIMES did you visit the emergency room in the PAST 6 MONTHS but were not admitted overnight?
  4. How many TIMES were you admitted to the hospital overnight in the PAST 6 MONTHS?
6 - 24 months
Relationship Satisfaction as assessed by the Dyadic Adjustment Scale (DAS)
Time Frame: 6 - 24 months
DAS is a 32-item questionnaire that measures an individual's perceptions of their relationship with an intimate partner. The scale has a total score range of 1-151 with a higher score indicating better satisfaction.
6 - 24 months
Diet as assessed by the Starting the Conversation (STC) Questionnaire
Time Frame: 6 - 24 months
STC is an 8-item simplified food frequency instrument designed for use in primary care and health-promotion settings. The instrument has a score range of 0-16 with a higher score indicating worse diet.
6 - 24 months
Sleep Quality as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 6 - 24 months
PSQI included 19self-rated items that assess sleep quality and disturbances over a 1-month time interval. The scale has a score range of 0-21, with a higher score indicating worse sleep quality.
6 - 24 months
Change in self-efficacy (Self-Efficacy for Managing Chronic Disease 6-item Scale)
Time Frame: Baseline to 6 months; baseline to 12 months; baseline to 24 months.
Change in SEMCD-6 total score. Scores range 1-10; higher scores indicate greater self-efficacy.
Baseline to 6 months; baseline to 12 months; baseline to 24 months.
Change in generalized anxiety symptoms (GAD-7)
Time Frame: Baseline to 6 months; Baseline to 12 months, Baseline to 24 months.
Change in GAD-7 total score. Scores range 0-21; higher scores indicate greater anxiety.
Baseline to 6 months; Baseline to 12 months, Baseline to 24 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Gabriela Ilie

Collaborators

Dalhousie University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 29, 2021

Primary Completion (Estimated)

April 1, 2030

Study Completion (Estimated)

October 1, 2031

Study Registration Dates

First Submitted

May 13, 2021

First Submitted That Met QC Criteria

May 17, 2021

First Posted (Actual)

May 20, 2021

Study Record Updates

Last Update Posted (Actual)

March 18, 2026

Last Update Submitted That Met QC Criteria

March 16, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PC_PEP_Phase 4_Protocol

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Prostate Cancer

Clinical Trials on Patient Empowerment Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe